Connecting phage bioinformatics with clinical translation: Global Phage Therapy Bridge 2027 

‍PrecisionPhage will host the Global Phage Therapy Bridge on 27–28 January 2027 in Singapore. This focused international gathering will bring together clinicians, scientists, regulators, manufacturers, bioinformatics experts and commercial decision-makers. 

The transition from a promising phage isolate to a clinically usable therapeutic product depends increasingly on reliable genomic information. Genome sequencing and bioinformatics are already necessary for phage identification, characterization and initial safety assessment. Sequencing and genomic data, however, offers much more: host-range estimation, manufacturing quality control, and the monitoring of genomic consistency.

“In phage therapy, genomic data can be a valuable asset for development, production and for obtaining regulatory approvals. We need reliable ways to generate, analyze, and interpret that data”, says Matti Jalasvuori, CEO of PrecisionPhage.  

While Global Phage Therapy Bridge is much more than bioinformatics, it is also a forum where the benefits of sequencing are discussed. Over two days, participants will delve into real-world clinical experience, emerging therapeutic solutions, regulatory pathways, manufacturing and GMP, reimbursement, patient access, and opportunities for concrete international collaboration. For the phage bioinformatics community, the meeting provides an important forum for considering how standardized genomic analysis, robust data infrastructure, and digital quality-control tools can support the translation of phages from discovery to clinical use. 

With limited attendance, the Global Phage Therapy Bridge offers a rare opportunity to connect bioinformatics and technology development directly with the clinical, manufacturing, regulatory, and commercial realities of phage therapy. 

Early registration is strongly recommended.